24^{th} WHO Expert Committee on Selection and Use of Essential Medicines Expert review

| A.4 | Anti-Ebola virus dis EML and EMLc | sease monoclonal antibodies – acute Ebola virus disease – |
|---|--|--|
| Draft recomm | endation | ☑ Recommended ☐ Not recommended Justification: Priority disease with high fatality, no other proven therapies |
| Does the proposed medicine address a relevant public health need? | | ✓ Yes ☐ No ☐ Not applicable Comments: |
| Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process) | | ✓ Yes ☐ No ☐ Not applicable Comments: Only one study, but no option for multiple studies given the nature of outbreaks |
| safety/harms a proposed med (this may be e application, ar | e evidence exist for the associated with the dicine? vidence included in the ad/or additional evidence ag the review process) | ☐ Yes ☑ No ☐ Not applicable Comments: |
| | adverse effects of at may require special | ☐ Yes ☑ No ☐ Not applicable Comments: |

24^{th} WHO Expert Committee on Selection and Use of Essential Medicines Expert review

| Are there any special requirements for the safe, effective and appropriate use of the medicines? (e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc) | ☐ Yes ☐ No ☐ Not applicable Comments: Confirmation of Zaire Ebola virus |
|--|---|
| Are there any issues regarding cost, cost- effectiveness, affordability and/or access for the medicine in different settings? | ✓ Yes ☐ No ☐ Not applicable Comments: No known cost |
| Are there any issues regarding the registration of the medicine by national regulatory authorities? (e.g. accelerated approval, lack of regulatory approval, off-label indication) | ☐ Yes ☐ No ☐ Not applicable Comments: Not yet registered in areas with Ebola |
| Is the proposed medicine recommended for use in a current WHO guideline? (refer to: https://www.who.int/publications/who-guidelines) | ✓ Yes ☐ No ☐ Not applicable Comments: |